Identification of binding domains of the growth hormone-releasing hormone receptor by analysis of mutant and chimeric receptor proteins

Molecular Endocrinology

Volumn 12, Issue 5, 1998, Pages 750-765

  DeAlmeida, V I ^a   Mayo, K E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; CHIMERIC PROTEIN; CYCLIC AMP; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR RECEPTOR; MUTANT PROTEIN; SECRETIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DNA FLANKING REGION; GENE ACTIVATION; GENE DELETION; GROWTH HORMONE RELEASE; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR BINDING;

EID: 0032230249     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/mend.12.5.0102     Document Type: Article

References (67)

1. Growth hormone-releasing hormone
2. Growth hormone releasing hormone
3. Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone
4. Pit-1-dependent expression of the receptor for growth hormone releasing factor mediates pituitary cell growth
5. Molecular cloning and expression of a human anterior pituitary receptor for growth hormone-releasing hormone
6. Structure and functional expression of a complementary DNA for porcine growth hormone-releasing hormone receptor
7. GHRH receptor of tittle mice contains a missense mutation in the extracellular domain that disrupts receptor function
8. Molecular basis of the little mouse phenotype and implications for cell type-specific growth
9. Nonsense mutation in the human growth hormone-releasing hormone receptor causes growth failure analogous to the little (lit) mouse
10. Identification of human growth hormone-releasing hormone receptor splicing variants
11. Identification of alternatively spliced messenger ribonucleic acid encoding truncated growth hormone-releasing hormone receptor in human pituitary adenomas
12. G Protein-Coupled Receptor Family B
13. Molecular cloning and expression of a cDNA encoding the secretin receptor
14. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide
15. Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor
16. Expression cloning and signaling properties of the rat glucagon receptor
17. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1
18. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain
19. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide
20. Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: A single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium
21. Expression cloning of a human corticotropin-releasing-factor receptor
22. Expression cloning of an adenylate cyclase-coupled calcitonin receptor
23. Receptors for secretin, calcitonin, parathyroid hormone (PTH)/PTH-related peptide, vasoactive intestinal peptide, glucagon-like peptide 1, growth hormone-releasing hormone and glucagon belong to a newly discovered G-protein-linked receptor family
24. Mutational analysis of cysteine residues within the extracellular domains of the human vasoactive intestinal peptide (VIP) 1 receptor identifies seven mutants that are defective in VIP binding
25. Highly conserved aspartate 68, tryptophane 73 and glycine 109 in the N-terminal extracellular domain of the human VIP receptor are essential for its ability to bind VIP
26. Synthesis and expression of a gene for the rat glucagon receptor. Replacement of an aspartic acid in the extracellular domain prevents glucagon binding
27. Receptors for VIP, PACAP, secretin, GRF, glucagon, GLP-1, and other members of their new family of G protein-linked receptors: Structure-function relationship with special reference to the human VIP-1 receptor
28. Speculations on the mechanism of hormone-receptor interactions of the secretin/glucagon family of polypeptide hormones derived from computational structural studies
29. Mutational analysis of muscarinic acetylcholine receptors: Structural basis of ligand/receptor/G protein interactions
30. Chimeric alpha 2-, beta 2-adrenergic receptors: Delineation of domains involved in effector coupling and ligand binding specificity
31. Molecular basis of the specificity of binding of glycoprotein hormones to their receptors
32. Mapping the ligand binding site of the NK-1 receptor
33. Identification of the amino acid residues involved in selective agonist binding in the first extracellular loop of the delta- and mu-opioid receptors
34. The ligand binding site of the angiotensin AT1 receptor
35. The isolated N-terminal extracellular domain of the glucagon-like peptide-1 (GLP)-1 receptor has intrinsic binding activity
36. Critical contributions of amino-terminal extracellular domains in agonist binding and activation of secretin and vasoactive intestinal polypeptide receptors. Studies of chimeric receptors
37. Properties of chimeric secretin and VIP receptor proteins indicate the importance of the N-terminal domain for ligand discrimination
38. The amino-terminal fragment of the adenylate cyclase activating polypeptide (PACAP) receptor functions as a high affinity PACAP binding domain
39. Lysine 173 residue within the first exoloop of rat secretin receptor is involved in carboxylate moiety recognition of Asp 3 in secretin
40. Multiple extracellular loop domains contribute critical determinants for agonist binding and activation of the secretin receptor
41. Aspartate 196 in the first extracellular loop of the human VIP1 receptor is essential for VIP binding and VIP-stimulated cAMP production
42. Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide receptor chimeras reveal domains that determine specificity of vasoactive intestinal polypeptide binding and activation
43. A putative selectivity filter in the G-protein-coupled receptors for parathyroid hormone and secretin
44. Glucagon.glucagon-like peptide I receptor chimeras reveal domains that determine specificity of glucagon binding
45. Chimeric human calcitonin and glucagon receptors reveal two dissociable calcitonin interaction sites
46. Characterization of deletion and truncation mutants of the rat glucagon receptor. Seven transmembrane segments are necessary for receptor transport to the plasma membrane and glucagon binding
47. The extracellular amino-terminal region of the parathyroid hormone (PTH)/PTH-related peptide receptor determines the binding affinity for carboxyl-terminal fragments of PTH-(1-34)
48. Homolog-scanning mutagenesis of the parathyroid hormone (PTH) receptor reveals PTH-(1-34) binding determinants in the third extracellular loop
49. Localization of the domains involved in ligand binding and activaton of the glucose-dependent insulinotropic polypeptide receptor
50. Localization of ligand-binding domains of human corticotropin-releasing factor receptor: A chimeric receptor approach
51. Growth hormone-releasing hormone: Synthesis and signaling
52. Reconstitution of functional muscarinic receptors by co-expression of amino- and carboxyl-terminal receptor fragments
53. Reconstitution of a high-affinity functional lutropin receptor by coexpression of its extracellular and membrane domains
54. Extracellular domain of lutropin/choriogonadotropin receptor expressed in transfected cells binds choriogonadotropin with high affinity
55. Human choriogonadotropin binds to a lutropin receptor with essentially no N-terminal extension and stimulates cAMP synthesis
56. Leutropin/beta-adrenergic receptor chimeras bind choriogonadotropin and adrenergic ligands but are not expressed at the cell surface
57. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions
58. Antibodies against specific extracellular epitopes of the glucagon receptor block glucagon binding
59. Epitope tagging and protein surveillance
60. A short polypeptide marker sequence useful for recombinant protein identification and purification
61. Engineering hybrid genes without the use of restriction enzymes: Gene splicing by overlap extension
62. Site-directed mutagenesis of virtually any plasmid by eliminating a unique site
63. Use of a hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes
64. Lipofection reagents prepared by a simple ethanol injection technique
65. A simple direct assay for cyclic AMP in plasma and other biological samples using an improved competitive protein binding technique